63
Participants
Start Date
March 31, 2008
Primary Completion Date
July 31, 2011
Study Completion Date
October 31, 2011
Fosbretabulin
Arm 2 only: Fosbretabulin (60 mg/m2) on Days 7,14 and 21 for 6 cycles.
Carboplatin
Chemotherapy: Carboplatin (AUC 6) on Day 1 of each 21 day cycle for 6 cycles.
Paclitaxel
Chemotherapy: Paclitaxel (20 mg/m2) on Day 1 of each 21-day cycle for 6 cycles.
Bevacizumab
Bevacizumab (15 mg/kg) on Day 1 of each 21-day cycle for 6 cycles.
Boca Raton Comprehensive Cancer Center, Boca Raton
Blueridge Cancer Care, Salem
Mary Babb Randolph Cancer Center-Clinical Trials Unit, Morgantown
Kentuckiana Cancer Institute, Louisville
The Mark H. Zangmeister Center, Columbus
Gabrail Cancer Center, Canton
Signal Point Clinical Research, Middletown
San Juan Oncology Associates, Farmington
UCLA Division of Hematology and Oncology, Los Angeles
Pacific Coast Hematology and Oncology Medical Group, Fountain Valley
Bay Area Cancer Research Group, LLC, Pleasant Hill
Southbay Oncology Hematology, Campbell
Northwest Medical Specialties, Tacoma
Lahey Clinic Medical Center, Burlington
The Center for Cancer and Hematologic Disease, Cherry Hill
Lead Sponsor
Mateon Therapeutics
INDUSTRY